Business Context and Reporting Period
Company: MyMD Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 21, 2023
Event: Entry into a Material Definitive Agreement for a registered direct offering.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic financial performance. Key metrics include:
- Gross Proceeds: Expected $15 million.
- Securities Issued: 15,000 shares of Series F Convertible Preferred Stock (stated value $1,000/share) and warrants to acquire up to 6,651,885 shares of Common Stock.
- Conversion/Exercise Price: $2.255 per share.
- Placement Agent Fee: 6% of gross proceeds.
- Use of Proceeds: General corporate purposes.
Note: The filing does not provide current revenue, profit, cash flow, or debt levels.
Material Changes and Transaction Terms
The Company entered into a Securities Purchase Agreement with accredited investors. Material terms include:
- Redemption Schedule: Preferred Shares must be redeemed in 12 equal monthly installments commencing July 1, 2023. Payments may be made in cash or Common Stock (subject to limitations).
- Dividends: 10% per annum, compounded monthly, payable in cash or stock. Rate increases to 15% upon a "Triggering Event" (e.g., failure to pay amounts due).
- Forced Conversion: Company may force conversion if Common Stock closes above $6.765 for 20 consecutive trading days with sufficient volume.
- Anti-Dilution: Warrants include a "full ratchet" adjustment if stock is issued below the exercise price.
- Stockholder Approval: Required by June 15, 2023, for issuance below the Nasdaq "Minimum Price." Approximately 44% of outstanding shares have agreed to vote in favor.
Outlook, Risks, and Contingencies
- Closing Conditions: The offering is expected to close on February 23, 2023, subject to customary conditions.
- Regulatory Risk: The Company must obtain stockholder approval to issue shares below the Nasdaq Minimum Price; failure to do so may limit the ability to settle conversions in stock.
- Liquidity Risk: There is no established public trading market for the Preferred Shares or Warrants.
- Covenants: The agreement imposes restrictions on indebtedness, acquisitions, liens, and asset transfers.
- Triggering Events: Failure to pay dividends or redemption amounts allows holders to demand immediate cash redemption at a premium.
Investor Verification Checklist
- Verify the final closing of the $15 million offering on or around February 23, 2023.
- Monitor the upcoming proxy statement for the June 15, 2023 stockholder vote on the issuance of shares below the Minimum Price.
- Review the Certificate of Designations (Exhibit 3.1) for specific definitions of "Triggering Events" and redemption premiums.
- Assess the impact of the 10% (or 15%) dividend obligation on future cash flow and liquidity.
- Check for any subsequent filings regarding the satisfaction of Nasdaq Rule 5635(d) requirements.